European Journal of Internal Medicine
Volume 19, Issue 1 , Pages 51-56 , January 2008

Postmenopausal Canarian women receiving oral glucocorticoids have an increased prevalence of vertebral fractures and low values of bone mineral density measured by quantitative computer tomography and dual X-ray absorptiometry, without significant changes in parathyroid hormone

  • M. Sosa

      Affiliations

    • University Hospital Insular, Department of Internal Medicine, Bone Metabolic Unit, University of Las Palmas de Gran Canaria, Investigation Group on Osteoporosis, Canary Islands, Spain
    • Corresponding Author InformationCorresponding author. University of Las Palmas de Gran Canaria, Investigation Group on Osteoporosis, Faculty of Medicine, Apartado 550, 35080, Las Palmas de Gran Canaria, Canary Islands, Spain. Tel.: +34 928451456; fax: +34 928451428.
    • ,
  • E. Jódar

      Affiliations

    • University Hospital 12 de Octubre, Endocrinology Division, Metabolic Bone Diseases Unit, Madrid, Spain
    • ,
  • P. Saavedra

      Affiliations

    • University of Las Palmas de Gran Canaria, Spain
    • ,
  • M.C. Navarro

      Affiliations

    • University of Las Palmas de Gran Canaria, Spain
    • ,
  • M.J. Gómez de Tejada

      Affiliations

    • University of Seville, Department of Medicine, Seville, Spain
    • ,
  • A. Martín

      Affiliations

    • University Hospital Insular, Department of Internal Medicine, Bone Metabolic Unit, University of Las Palmas de Gran Canaria, Investigation Group on Osteoporosis, Canary Islands, Spain
    • ,
  • P. Peña

      Affiliations

    • University Hospital Insular, Department of Internal Medicine, Bone Metabolic Unit, University of Las Palmas de Gran Canaria, Investigation Group on Osteoporosis, Canary Islands, Spain
    • ,
  • J. Gómez

      Affiliations

    • University Hospital Insular, Department of Internal Medicine, Bone Metabolic Unit, University of Las Palmas de Gran Canaria, Investigation Group on Osteoporosis, Canary Islands, Spain

Received 17 December 2006 ,Revised 28 August 2007 ,Accepted 30 August 2007.

References 

  1. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359:1761–1767
  2. Cushing H. The basophilic adenomas of pituitary body and their clinical manifestations (pituitary basophilism). Johns Hopkins Hosp Bull. 1932;1:137–192
  3. Khosla S, Lufkin EG, Hodgson SF, Fitzpatrick LA, Melton LJ. Epidemiology and clinical features of osteoporosis in young individuals. Bone. 1994;15:551–555
  4. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis . Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 2001;44:1496–1503
  5. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, et al. A UK consensus group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med. 1998;244:271–292
  6. Geusens PP, de Nijs RNJ, Lems WF, Laan RFJM, Struijs A, Van Staa TP, et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society of Rheumatology. Ann Rheum Dis. 2004;63:264–265
  7. Homik JE, Cranney A, Shea B, Tugwell P, Wells G, Adachi J. A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis. J Rheumatol. 1999;26:1148–1157
  8. Kanis JA, Glüer CC for the Committee of Scientific Advisors, International Osteoporosis Foundation. An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int. 2000;11:192–202
  9. Cann CE. Quantitative CT for determination of bone mineral density: a review. Radiology. 1988;166:509–522
  10. Rehman Q, Lang T, Modin G, Lane NE. Quantitative computed tomography of the lumbar spine, not dual X-ray absorptiometry, is an independent predictor of prevalent vertebral fractures in postmenopausal women with osteopenia receiving long-term glucocorticoid and hormone-replacement therapy. Arthritis Rheum. 2002;46:1292–1297
  11. Rubin MR, Bilezikian JP. The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis. A re-examination of the evidence. J Clin Endocrinol Metab. 2002;87:4033–4041
  12. Lukert BP. Glucocorticoid-induced osteoporosis. In:  Favus MJ editors. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Fifth Edition. Washington: ASBMR; 2003;p. 364–370
  13. Van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int. 2006;79:129–137
  14. O’Neill TW, Cooper C, Cannata JB, Díaz López JB, Hoszowski K, Johnell O, et al. on behalf the European Vertebral Osteoporosis Study (EVOS) Reproducibility of a questionnaire on risk factors for osteoporosis in a multicentre prevalence survey: the European Vertebral Osteoporosis Study. Int J Epidemiol. 1994;23:559–565
  15. Genant HK, Wu CY, van Kujic C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137–1148
  16. Sosa M, Hernández D, Estévez S, Limiñana JM, Saavedra P, Láinez P. The range of bone mineral density in healthy Canarian women by dual X-ray absorptiometry radiograghy and quantitative computer tomography. J Clin Densitom. 1998;1:385–393
  17. Cann CE, Genant HK. Precise measurement of the vertebral mineral content using computed tomography. J Comput Assist Tomogr. 1980;4:493–500
  18. Genant HK, Steiger P, Block JE, Glueer CC, Ettinger B, Harris ST. Quantitative computed tomography: update 1987. Calcif Tissue Int. 1987;41:179–186
  19. Pacifici R, Rupich R, Griffin M, Chines A, Susman N, Avioli LV. Dual energy radiography versus quantitative computer tomography for the diagnosis of osteoporosis. J Clin Endocrinol Metab. 1990;70:705–710
  20. Adachi J, Bensen W, Hodsman AB. Corticosteroid-induced osteoporosis. Semin Arthritis Rheum. 1993;22:375–384
  21. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1998;339:292–299
  22. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-bind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999;42:2309–2318
  23. Van Staa TP, Van Staa RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003;48:3224–3229
  24. Ross PD, Davis J, Epstein R, Wasnick R. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med. 1991;114:919–923
  25. Angeli A, Gugliemi G, Dovio A, Capelli G, de Feo D, Giannini S, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone. 2006;39:253–259
  26. Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int. 2004;15:323–328
  27. De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007;56:208–214
  28. Cooper C, O'Neill T, Silman A on behalf of the European Vertebral Osteoporosis Study Group (EVOS). The epidemiology of vertebral fractures. Bone. 1993;14:589–597
  29. Harvey N, Earl S, Cooper C. Epidemiology of osteoporotic fractures. In:  Favus MJ editors. Primer on the Metabolic Disease and Disorders of Mineral Metabolism. 6th Edition. Washington: American Society for Bone and Mineral research; 2006;p. 244–248
  30. Fucik RF, Kukreja SC, Hargis GK, Bowser EN, Henderson WJ, Williams GA. Effect of glucocorticoids on function of the parathyroid glands in man. J Clin Endocrinol Metab. 1975;40:152–155

PII: S0953-6205(07)00257-9

doi: 10.1016/j.ejim.2007.08.005

European Journal of Internal Medicine
Volume 19, Issue 1 , Pages 51-56 , January 2008

Article Tools

* Image Usage & Resolution